Trials / Recruiting
RecruitingNCT06980649
Study of BHV-1300 in Graves' Disease
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-1300 | BHV-1300 is delivered subcutaneously (SC) |
Timeline
- Start date
- 2025-08-21
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2025-05-20
- Last updated
- 2026-03-12
Locations
13 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06980649. Inclusion in this directory is not an endorsement.